布地奈德联合肺表面活性物质治疗新生儿呼吸窘迫综合征的临床研究  

Clinical Study of Budesonide Combined with Pulmonary Surfactant for Treating Neonatal Respiratory Distress Syndrome

作　　者：蔡琳 李晓东[1] 张升荣 江斓燕 田青[1] 陈宏洁 CAI Lin;LI Xiaodong;ZHANG Shengrong;JIANG Lanyan;TIAN Qing;CHEN Hongjie(Huazhong University of Science and Technology Union Shenzhen Hospital,Shenzhen 518052,China;不详)

机构地区：[1]华中科技大学协和深圳医院,深圳市南山区人民医院,广东深圳518052

出　　处：《中外医学研究》2020年第29期8-11,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：深圳市南山区区级科研课题项目(南科研卫2016029号)。

摘　　要：目的:探讨布地奈德联合肺表面活性物质(PS)治疗新生儿呼吸窘迫综合征(NRDS)的临床效果。方法:选取早产儿中出生体重≤1500 g或胎龄≤32周、诊断新生儿呼吸窘迫综合征(NRDS)、需要呼吸支持的患儿123例,随机分为治疗组(n=61,布地奈德+PS)和对照组(n=62,PS)。比较两组重复使用PS率、有创通气率、血气分析、氧合指数(OI)、呼吸机通气时间、吸氧时间、住院时间、住院费用、BPD发生率、其他合并症的发生率及病死率。结果:两组重复使用PS率、有创通气率、住院时间、住院费用及病死率比较,差异无统计学意义(P>0.05)。治疗组患儿在给药后2、48 h动脉血气pH、PaO2、OI均高于对照组,PaCO2低于对照组,差异均有统计学意义(P<0.05);治疗组患儿呼吸机通气时间、吸氧时间均短于对照组,BPD发生率低于对照组,差异均有统计学意义(P<0.05);两组其他合并症发生率差异无统计学意义(P>0.05)。结论:布地奈德联合PS较单用PS能更有效治疗NRDS,并降低BPD的发生率,并未增加合并症发生率。Objective:To explore the clinical efficacy of Budesonide combined with pulmonary surfactant(PS)for treating neonatal respiratory distress syndrome.Method:A total of 123 preterm infants with birth weight≤1500 g or gestational age≤32 weeks,who diagnosed as respiratory distress syndrome(NRDS)and need respiratory support were randomly divided into the treatment group(61 cases,Budesonide+PS)and the control group(62 cases,PS).The PS reuse rate,invasive ventilation rate,arterial blood gas analysis,oxygenation index(OI),duration of mechanical ventilation,duration of oxygen supplementation,duration of hospital stay,medical expense,incidence of BPD,incidence of other complications except BPD and mortality were compared between the two groups.Result:Comparison of PS rate,invasive ventilation rate,duration of hospital stay,medical expense and mortality between the two groups showed no statistically significant difference(P>0.05).At 2 h,48 h after administration,arterial blood gas pH,PaO2,OI in the treatment group were higher than those in the control group,and PaCO2 was lower than that in the control group,and the differences were statistically significant(P<0.05).Compared with the control group,the treatment group had shorter duration of mechanical ventilation and oxygen supplementation,lower incidence of BPD,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of other complications except BPD between the two groups(P>0.05).Conclusion:Compared with PS alone,Budesonide+PS can effectively treat NRDS and reduce the incidence of BPD,but does not increase the incidence of complications.

关 键 词：布地奈德 肺表面活性物质 新生儿呼吸窘迫综合征 早产儿 

分 类 号：R722.1[医药卫生—儿科]